Acquired Company

Bristol-Myers Squibb acquired 2seventy bio on 5/13/2025 for $5.00 per share in cash, representing a total equity value of approximately $286 million.

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. Show more

60 Binney Street, Cambridge, MA, 02142, United States

Biotechnology

Healthcare

Start AI Chat

Market Cap

266.1M

52 Wk Range

$2.29 - $5.30

Previous Close

$5.00

Open

$5.00

Volume

N/A

Day Range

$5.00 - $5.00

Enterprise Value

335.5M

Cash

170.4M

Avg Qtr Burn

-13.52M

Insider Ownership

6.44%

Institutional Own.

82.40%

Qtr Updated

03/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ABECMA (IDE-CE) (bb2121) Details Cancer, Multiple myeloma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ABECMA (IDE-CEL) (bb2121) Details Cancer, Multiple myeloma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
bbT369 Details Cancer, Non-Hodgkin lymphoma, B-cell lymphoma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SC-DARIC33 Details Cancer, Acute myeloid leukemia, Relapsed/refractory acute myeloid leukemia	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.